

OPEN ACCESS ORIGINAL REPORTS March 20, 2023



ADVERTISEMENT

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated



Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)

Authors: [Roger Olofsson Bagge, MD, PhD](#), [Axel Nelson, MD, PhD](#), [Amir Shafazand, MD](#), [Charlotta All-Eriksson, MD, PhD](#), [Christian Cahlin, MD, PhD](#), [Nils Elander, MD, PhD](#), [Hildur Helgadóttir, MD, PhD](#), ... [SHOW ALL](#) ..., and [Per Lindnér, MD, PhD](#) | [AUTHORS INFO & AFFILIATIONS](#)

Publication: Journal of Clinical Oncology Volume 41, Number 16
<https://doi-org.ezproxy.ub.gu.se/10.1200/JCO.22.01705>

ADVERTISEMENT

4 420



FULL TEXT HTML (Hypertext Markup Language)

[Check for updates](#)

Downloaded from ascpubs.org by GÖTEBORGS UNIVERSITET on January 8, 2024 from 130.241.106.016
Copyright © 2023, American Society of Clinical Oncology. All rights reserved.

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)

Roger Olofsson Bagge, MD, PhD^{1,2,3}; Axel Nelson, MD, PhD⁴; Amir Shafazand, MD^{5,6}; Charlotta All-Eriksson, MD, PhD⁷; Christian Cahlin, MD, PhD⁸; Nils Elander, MD, PhD⁹; Hildur Helgadóttir, MD, PhD¹⁰; Jens Folke Kilgaard, MD, PhD¹¹; Sara Kinshult, MD, PhD¹²; Ingrid Ljuslinder, MD, PhD¹³; Jan Mattsson, MD, PhD¹⁴; Magnus Ritzell, MD, PhD¹⁵; Malin Stenby Eliand, MD, PhD¹⁶; Gustav J. Ullenbg, MD, PhD^{17,18}; Jonas A. Nilsson, PhD^{19,20}; Lars Ny, MD, PhD²¹; and Per Lindnér, MD, PhD²²

original reports

PURPOSE About half of patients with metastatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 months. The few systemic treatment options available only moderately prolong survival. Isolated hepatic perfusion (IHP) with melphalan is a regional treatment option, but prospective efficacy and safety data are lacking.

METHODS In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group). The primary end point was overall survival at 24 months. Here, we report the secondary outcomes of response according to RECIST 1.1 criteria, progression-free survival (PFS), hepatic PFS (hPFS), and safety.

RESULTS Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44). In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP. In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively (P < .0001). The median PFS was 7.4 months versus 3.3 months (P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months (P < .0001), both favoring the IHP arm. There were 11 treatment-related serious adverse events in the IHP group compared with seven in the control group. There was one treatment-related death in the IHP group.

CONCLUSION IHP treatment resulted in superior ORR, hPFS, and PFS compared with best alternative care in previously untreated patients with isolated liver metastases from primary uveal melanoma.

J Clin Oncol 41:3042-3050. © 2023 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License

INTRODUCTION Uveal melanoma is a rare disease accounting for approximately 3% of all melanomas. Even when the primary tumor is successfully eradicated from the eye by surgery or radiotherapy, approximately 50% of patients will develop metastases.¹ Metastases are strongly hepatotropic, with isolated liver metastases seen in over half of patients with metastatic disease. Among these patients, the median survival is approximately 10-12 months and only a few patients

outcomes reflect generally poor responses to systemic chemotherapy, which shows minimal efficacy and delivers no detectable survival benefit. In contrast to cutaneous melanoma, immune checkpoint inhibition (ICI) has been of only limited benefit in patients with uveal melanoma, with the combination of ipilimumab and nivolumab showing an overall response rate (ORR) of 10%-18% and an uncertain impact on survival.^{3,5} The combination of pembrolizumab and epigenetic therapy with a

ASSOCIATED CONTENT

Protocol

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on February 9, 2023 and published at ascopubs.org/journal/jco on March 20, 2023; DOI: <https://doi.org/10.1200/JCO.22.01705>

ASCO Career Center

 [DOWNLOAD PDF](#)

Prior Presentation

Presented at the 2022 ASCO annual meeting, Chicago, IL, June 3-7, 2022.

Support

Supported by grants from the Signe and Olof Wallenius Foundation, The Assar Gabrielsson Foundation, Gothenburg Society of Medicine, Wilhelm and Martina Lundgrens Foundation, The Erling-Persson Foundation, Knut and Alice Wallenberg Foundation, The Swedish Cancer Society, and The Swedish Research Council.

Clinical Trial Information

[NCT01785316](#) (EudraCT number: 2013-000564-29)

ASCO Career Center

Clinical Assistant Professor or Clinical Associate Professor (Melanoma-Renal)
Seattle, Washington State | Salary and faculty rank will be commensurate based on qualifications.

Recruiting for a full-time faculty member to join the Melanoma-Renal group.

Employer: University of Washington - Dept. of Medicine
[Apply for this job](#)

Hematology/Oncology Hospitalist

Providence, Rhode Island (US) | Competitive Salary and Benefits Package  BROWN UNIVERSITY

Recruiting a BC/BE Hematologist/Oncologist hospitalist to oversee the solid tumor teaching service at Rhode Island Hospital.

Employer: Brown University/Rhode Island Hospital
[Apply for this job](#)

ADVERTISEMENT

Recommended Articles

APR 01, 1998

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.

DEC 01, 1986

Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard).

MELANOMA/SKIN CANCERS | JUN 08, 2022

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial).

FEB 01, 1996

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.

MELANOMA | SEP 01, 2006

Randomized Multicenter Trial of Hyperthermic Isolated Limb Perfusion With Melphalan Alone Compared With Melphalan Plus Tumor Necrosis Factor: American College of Surgeons Oncology Group Trial Z0020

[View full text](#)

JOURNALS

Journal of Clinical
Oncology
JCO Oncology Practice
JCO Global Oncology
JCO Clinical Cancer
Informatics
JCO Precision
Oncology

PUBLICATIONS

ASCO Educational Book
ASCO Daily News
ASCO Connection
The ASCO Post
ASCO Podcasts

CONTENT

Journal Podcasts
Topics
Meeting Abstracts
ASCO Guidelines

INFORMATION

Author Center
Subscriber Center
Permissions
Reprints
Advertise
E-Alerts
View My Profile
About ASCO Journals

FOLLOW US

JCO_ASCO
JCOOP_ASCO
JCOGO_ASCO
JCOPO_ASCO
JCOCC_ASCO

ASCO

About ASCO
Press Center
Meetings & Education
Contact Us

ASCO WEBSITES

asco.org
ASCO Career Center
Conquer Cancer

American Society of Clinical Oncology
2318 Mill Road, Suite 800, Alexandria, VA 22314
© 2024 American Society of Clinical Oncology

[Site Map](#) | [Terms of Use](#) | [Privacy Policy](#) | [Cookies](#)